Evidence: Strong human evidence (Phase 3) for HIV lipodystrophy; reduces visceral fat.
In context: FDA-approved (Egrifta). Renova supplies it for research only. GH/IGF-1 pro-growth; may affect glucose.
Research range · SC
1.4–2 mg per application· once daily
🟢 Clinical evidence
Ranges cited in research literature. Not a usage recommendation. For research use only.
📋 Technical datasheet · Compound specifications
Compound
Tesamorelina
Origin
🇺🇸 From US-based suppliers that follow strict cGMP & ISO 9001 guidelines
Form
Lyophilized in sterile vial (or pre-mixed solution depending on SKU)
Molecular formula
C221H366N72O67S
Molecular weight
5135.85 g/mol
Sequence
GHRH(1-44) + hexenoyl
Purity
98.59% by HPLC + mass spectrometry (Janoshik Analytical)
Storage
Lyophilized: −20°C to −80°C, dry, dark · Reconstituted: 2–8°C · stability varies by peptide (see the reconstitution guide and the batch COA)
Recommended solvent
Bacteriostatic water (0.9% benzyl alcohol) or 0.9% saline
Cold chain
2–8°C in transit · controlled thermal packaging
Use
Research Use Only (RUO). Not intended for human or veterinary use.
Typical values for this compound category. For product-specific data, see the corresponding COA at /en/coa/.
🧪 Independent third-party analysis available — Janoshik Analytical (HPLC + MS).View all COAs →
This product is exclusively for research purposes. Not intended for human use, consumption, or therapeutic applications. For laboratory use only under qualified supervision.